The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma

Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome

(2014) N. Shenoy et al.   BLOOD

The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia

(2014) Ashish Banerjee et al.   BRITISH JOURNAL OF HAEMATOLOGY

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

(2014) Elena Maria Elli et al.   Mediterranean Journal of Hematology and Infectious Diseases

Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status

(2013) Dae-Hyoung Lee et al.   EXPERIMENTAL HEMATOLOGY

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

(2012) N. Gattermann et al.   HAEMATOLOGICA

Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma

(2012) Liat Vazana-Barad et al.   LEUKEMIA & LYMPHOMA

The effect of iron overload and chelation on erythroid differentiation

(2011) Kazuki Taoka et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

(2010) E. Messa et al.   HAEMATOLOGICA

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review

(2010) Roberto Guariglia et al.   LEUKEMIA RESEARCH

Inhibition of Constitutively Activated Nuclear Factor- B Induces Reactive Oxygen Species- and Iron-Dependent Cell Death in Cutaneous T-Cell Lymphoma

(2009) M. K. Kiessling et al.   CANCER RESEARCH

Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis

(2008) E. Messa et al.   ACTA HAEMATOLOGICA

Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents

(2008) D.R. Richardson et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS